Published in Mol Cell Biochem on January 01, 2001
Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes. J Natl Cancer Inst (2013) 1.45
Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells. PLoS One (2014) 0.75
Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins. Pharmaceuticals (Basel) (2011) 0.75
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med (1999) 7.56
SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer. Oncologist (2000) 6.24
Smoking and causes of death among U.S. veterans: 16 years of observation. Public Health Rep (1980) 3.00
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer (2007) 2.71
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
Ovarian carcinomas with transitional cell carcinoma pattern. Am J Clin Pathol (1990) 2.70
Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol (2001) 2.05
Breaking bad news about cancer: patients' preferences for communication. J Clin Oncol (2001) 2.00
Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol (2000) 1.95
Overproduction of protein kinase C causes disordered growth control in rat fibroblasts. Cell (1988) 1.91
Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med (1995) 1.89
Paget's disease of the vulva: pathology, pattern of involvement, and prognosis. Gynecol Oncol (2000) 1.82
The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev (1993) 1.74
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol (2001) 1.73
Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness. Cancer (1999) 1.73
Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol (2001) 1.59
Isolation of cDNA clones encoding protein kinase C: evidence for a protein kinase C-related gene family. Proc Natl Acad Sci U S A (1987) 1.59
Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab (1998) 1.57
Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol (1999) 1.56
Inhibition of protein kinase C by tamoxifen. Cancer Res (1985) 1.56
Primary medical management of recurrent aggressive angiomyxoma of the vulva with a gonadotropin-releasing hormone agonist. Gynecol Oncol (2001) 1.55
Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential. Int J Gynecol Pathol (1998) 1.54
Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (1999) 1.53
Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer (1992) 1.50
Prognostic factors in adult granulosa cell tumor of the ovary. Cancer (1997) 1.49
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. J Clin Oncol (2000) 1.46
Medical student interest in alternative medicine. J Altern Complement Med (2000) 1.44
Groin dissection practices among gynecologic oncologists treating early vulvar cancer. Gynecol Oncol (1996) 1.43
Secretion of creatine kinase MB isoenzyme by an immature teratoma with predominant rhabdomyosarcomatous elements. Clin Chem (1988) 1.40
Twenty-eight loci form a continuous linkage map of markers for human chromosome 1. Genomics (1989) 1.40
Papillary serous carcinoma of the peritoneum. Obstet Gynecol (1990) 1.33
Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. Gynecol Oncol (1996) 1.33
Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. J Cancer Educ (1997) 1.32
Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab (2006) 1.27
Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol (1989) 1.24
Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med (1986) 1.23
Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience. Oncol Rep (1998) 1.21
Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res (1989) 1.20
Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. J Mol Biol (2000) 1.19
Oxidant-induced S-glutathiolation inactivates protein kinase C-alpha (PKC-alpha): a potential mechanism of PKC isozyme regulation. Biochemistry (2000) 1.19
Hemorrhagic cystitis following radiotherapy for stage Ib cancer of the cervix. Gynecol Oncol (1994) 1.18
Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol (2001) 1.17
Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol (2001) 1.14
Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin Exp Metastasis (2000) 1.14
Paraneoplastic syndromes of gynecologic neoplasms. J Clin Oncol (1997) 1.13
Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med (1998) 1.12
Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol (1997) 1.11
Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res (2001) 1.11
Standardized histologic grading of epithelial ovarian cancer: elusive after all these years. Gynecol Oncol (1998) 1.10
Sexual dysfunction and treatment for early stage cervical cancer. Cancer (1989) 1.10
Discussing disease progression and end-of-life decisions. Oncology (Williston Park) (1999) 1.10
Monoclonal antibody therapy for solid tumors. Cancer Treat Rev (2000) 1.09
Analysis of the severe complications of irradiation of carcinoma of the cervix: whole pelvis irradiation and intracavitary radium. Int J Radiat Oncol Biol Phys (1983) 1.08
Immature teratoma of the ovary. Obstet Gynecol (1986) 1.07
Central nervous system neurocytoma and neuroblastoma in adults--report of eight cases. J Neurooncol (1990) 1.07
Sigmoid perforation following radiation therapy in patients with cervical cancer. Gynecol Oncol (2001) 1.07
Biology of the protein kinase C family. Cancer Metastasis Rev (1989) 1.07
Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol (1993) 1.07
Mixed germ cell tumors of the ovary. Obstet Gynecol (1984) 1.06
Intraoperative lymphatic mapping for vulvar cancer. Obstet Gynecol (1994) 1.06
Intraperitoneal catheters: percutaneous placement with fluoroscopic guidance. J Vasc Interv Radiol (1993) 1.06
Triphenylethylenes: a new class of protein kinase C inhibitors. J Natl Cancer Inst (1986) 1.05
Protein kinase C phosphorylates the synthetic peptide Arg-Arg-Lys-Ala-Ser-Gly-Pro-Pro-Val in the presence of phospholipid plus either Ca2+ or a phorbol ester tumor promoter. Biochem Biophys Res Commun (1984) 1.04
Non-Hodgkin's lymphoma involving the vagina: a clinicopathologic analysis of 14 patients. Am J Surg Pathol (2000) 1.04
Editorial: Impact of Cancer: years of life lost due to cancer mortality. J Natl Cancer Inst (1974) 1.03
Subtorcular occipital encephaloceles. Anatomical considerations relevant to operative management. J Neurosurg (1989) 1.03
Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol (1999) 1.02
Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med (1996) 1.02
Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol (1992) 1.01
Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res (1996) 1.01
Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol (1988) 1.01
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer (2005) 1.00
Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model. Cancer Gene Ther (2006) 1.00
Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res (2001) 0.99
Echocardiographic evaluation of potential cardiac transplant donors. J Thorac Cardiovasc Surg (1988) 0.98
Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res (1991) 0.98
Altered levels of protein kinase C and Ca2+-dependent protein kinases in human colon carcinomas. Cancer Res (1987) 0.98
Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol (1991) 0.98
Single-agent cis-platinum therapy for advanced ovarian cancer. Obstet Gynecol (1981) 0.98
Adenoid cystic carcinoma of Bartholin gland. Obstet Gynecol (1986) 0.98
Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells. FEBS Lett (1989) 0.98
The regulation of protein kinase C by chenodeoxycholate, deoxycholate and several structurally related bile acids. Carcinogenesis (1987) 0.98
Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res (1989) 0.97
Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy. Surgery (2001) 0.97
Bone marrow in the acquired immunodeficiency syndrome. Ann Intern Med (1984) 0.97
Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Obstet Gynecol (1990) 0.97
Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol (1985) 0.97
Characterization of 13 novel band 3 gene defects in hereditary spherocytosis with band 3 deficiency. Blood (1996) 0.97
Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol (2001) 0.97
Identification of a second T-cell antigen receptor in human and mouse by an anti-peptide gamma-chain-specific monoclonal antibody. Proc Natl Acad Sci U S A (1987) 0.97
Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol (2000) 0.96
Activation of tumoricidal properties in macrophages by lipopolysaccharide requires protein-tyrosine kinase activity. J Leukoc Biol (1993) 0.96
High-risk metastatic gestational trophoblastic disease. Obstet Gynecol (1985) 0.95
Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol (1998) 0.95
Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphasis Tumor Immunol (1994) 0.94
Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer (1985) 0.94
Enterovesical fistula following radiotherapy for gynecologic cancer. Gynecol Oncol (1994) 0.94